Marshall Wace’s NeuroSense Therapeutics NRSN Stock Holding History

Marshall Wace’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,828	Closed	-$22.4K	–	3237
2025 Q2	$22.4K	Buy	+11,828	New	+$17.1K	﹤0.01%	2628

Other funds holding NRSN

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Marshall Wace's NRSN Position: Q3 2025 in Review

Marshall Wace sold out of NeuroSense Therapeutics (NRSN) in Q3 2025, closing a stake of 11,828 shares — an estimated $22.4K sold.

Marshall Wace first reported a position in NRSN in Q2 2025 and held it in 1 quarter. The position peaked at $22.4K in Q2 2025. 10 funds tracked by Wall St. Rank hold NRSN as of Q3 2025.

Marshall Wace reported no remaining NeuroSense Therapeutics position as of Q3 2025 after selling out during the quarter.
Marshall Wace sold 11,828 NeuroSense Therapeutics shares in Q3 2025, an estimated $22.4K.
Marshall Wace first reported a position in NeuroSense Therapeutics in Q2 2025 and held it in 1 quarter.
Marshall Wace's NeuroSense Therapeutics position peaked at $22.4K in Q2 2025.
10 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.